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Abstract
Context—Effective community-based interventions are available to control hypertension. It is 
important to determine the economics of these interventions.
Evidence acquisition—Peer-reviewed studies from January 1995 through December 2015 
were screened. Interventions were categorized into educational interventions, self-monitoring 
interventions, and screening interventions. Incremental cost-effectiveness ratios were summarized 
by types of interventions. The review was conducted in 2016.
Evidence synthesis—Thirty-four articles were included in the review (16 from the U.S., 18 
from other countries), including 25 on educational interventions, three on self-monitoring 
interventions, and six on screening interventions. In the U.S., five (31.3%) studies on educational 
interventions were cost saving. Among the studies that found the interventions cost effective, the 
median incremental costs were $62 (range, $40–$114) for 1-mmHg reduction in systolic blood 
pressure (SBP) and $13,986 (range, $6,683–$58,610) for 1 life-year gained. Outside the U.S., 
educational interventions cost from $0.62 (China) to $29 (Pakistan) for 1-mmHg reduction in SBP. 
Self-monitoring interventions, evaluated in the U.S. only, cost $727 for 1-mmHg reduction in SBP 
and $41,927 for 1 life-year gained. For 1 quality-adjusted life-year, screening interventions cost 
from $21,734 to $56,750 in the U.S., $613 to $5,637 in Australia, and $7,000 to $18,000 in China. 
Intervention costs to reduce 1 mmHg blood pressure or 1 quality-adjusted life-year were higher in 
the U.S. than in other countries.
Conclusions—Most studies found that the three types of interventions were either cost effective 
or cost saving. Quality of economic studies should be improved to confirm the findings.
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CONTEXT
Hypertension, a major risk factor for cardiovascular disease (CVD), has an estimated cost of 
approximately $48.6 billion annually in the U.S.1 Although awareness of hypertension and 
its control have been improving, about one in seven adults with high blood pressure are 
unaware of it.2 The medication adherence rate remains suboptimal,2 and 46% of adults with 
hypertension in 2013–2014 did not have their high blood pressure under control.2
Community-based interventions for controlling high blood pressure, such as engaging 
community health workers in hypertension prevention, team-based care to improve blood 
pressure control, and screening for high blood pressure, have played a vital role in reducing 
morbidity and mortality from CVD.3 From 1980 to 2000, it was estimated that reduction in 
major risk factors contributed to the 50% reduction in mortality from coronary heart disease 
(CHD) in the U.S.4 Although several systematic reviews have shown that many community-
based interventions are effective to help improve blood pressure control in the community,5,6 
few reviews have looked at the cost effectiveness and overall economic implications of the 
programs. Those reviews that summarized economic evidence regarding a particular 
program, such as team-based care and self-monitoring interventions, did not evaluate the 
quality of the studies.7,8
This study summarizes evidence on cost effectiveness of community-based interventions to 
control hypertension based on a review of the literature published in the past 2 decades. The 
authors categorized the evidence by types of interventions and types of health professionals 
delivering the interventions, and a critical assessment was conducted to evaluate the quality 
of the studies. Although the review focuses primarily on the evidence of cost effectiveness, 
studies using all three types of economic methodologies are searched and include cost-
effectiveness analysis (CEA); cost–utility analysis (CUA); and cost–benefit analysis (CBA). 
CEA measures benefit as a single unidimensional outcome (e.g., blood pressure, disease 
events prevented, and life-years saved). CUA uses health-related quality of life as the only 
benefit measure, whereas CBA assigns monetary values to healthcare benefits. The evidence 
can inform policymakers, payers, and practitioners of the economic implications of various 
interventions for controlling high blood pressure among hypertensive patients in the 
community.
EVIDENCE ACQUISITION
Literature Search Strategy
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were 
applied for this systematic review.9 Peer-reviewed literature published in English during 
January 1995 through December 2015 were searched from the databases of PubMed, 
CINAHL, MEDLINE, EMBASE, EconLit, Cochrane Library, and PsycINFO. Searched key 
terms included the following:
Interventions—community health worker or community-based or community-based 
interventions or community-clinical coordination or outreach services or culturally 
competent services or promoters or community health education;
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Study types—cost benefit or cost effectiveness or cost utility or economic evaluation or 
budget impact analysis;
Study outcomes—hypertension or high blood pressure or diastolic or systolic or quality-
adjusted life years or QALYs or life years gained or disability-adjusted life years or DALYs.
Inclusion and Exclusion Criteria
Only studies with an economic evaluation of interventions for hypertension control among 
hypertensive patients in community rather than clinical settings were included. The 
following studies were excluded:
1. duplicated literature;
2. articles that were not hypertension related or did not target hypertensive patients;
3. articles that were not CEA, CUA, or CBA;
4. articles with an incomplete economic evaluation of a program or evaluation on 
the cost for hypertension drugs only;
5. studies that focused on non-community-based interventions such as clinical 
research, or studies conducted in a particular setting such as worksite or school;
6. review articles and commentaries; and
7. abstract-only articles or conference presentations without a full-text manuscript.
Among 615 articles identified from the literature search that were potentially relevant, 64 
articles were selected after applying exclusion criteria 1–5. Two authors independently 
selected the articles to be included in the review. If the two authors disagreed on whether a 
study should be included, they discussed it with the third author. After excluding review 
articles, commentaries, and abstract-only articles, 34 articles met the criteria for this review 
(Figure 1).
Data Extraction and Synthesis
Selected studies were classified by countries (U.S. versus outside of U.S.); types of 
interventions; and types of providers. A framework in a Cochrane systematic review study 
on the effectiveness of hypertension control interventions was used as a reference,6 and 
types of interventions were classified into three groups:
1. educational interventions including educational interventions for lifestyle 
modification, educational interventions for medication adherence, and 
educational interventions for both lifestyle modification and medication 
adherence;
2. blood pressure self-monitoring interventions with community assistance; and
3. community-based screening including population-based screening and 
identification of hypertension cases, combined with intensive treatment of 
hypertensive patients, and targeted outreach screening with management of 
identified hypertension cases.
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As a secondary classification strategy, the studies were categorized by types of providers 
who conducted the interventions:
1. physician providers;
2. non-physician providers (including those who practice either in collaboration 
with or under the supervision of a physician such as nurse practitioners and 
physician assistants); and
3. both physician and non-physician providers.
Also, the titles of the articles, authors, publication year, intervention setting, study 
population, study approaches, time horizon, study perspectives, major outcome measures, 
study quality, main findings, and conclusions of each study were recorded. Quality of each 
study was assessed according to the Consensus on Health Economic Criteria.10 The criteria 
are a set of 19 items to assess the methodologic quality of economic evaluations, developed 
by experts using a Delphi method.10 Among the items are research questions, target 
population, study design, time horizon, economic evaluation perspectives, cost 
measurement, cost inflation, outcome measurement, cost discounting, outcome discounting, 
sensitivity analysis, study generalizability, potential conflict of interest, and ethical concerns. 
Two authors independently assessed the quality of all 34 studies by placing a check mark 
next to the criterion that the study had met. Group discussions were conducted to settle any 
disagreement during the process of quality assessment.
The review was conducted in 2016. Incremental cost-effectiveness ratios (ICERs) and net 
cost savings by country and types of interventions were summarized. ICERs were adjusted 
to 2014 U.S. dollars using purchasing power parity exchange rates from the World Bank and 
the consumer price index medical care component from the Bureau of Labor Statistics.11,12
EVIDENCE SYNTHESIS
Description of the Literature
Of the 34 selected studies, there were ten studies of educational interventions for lifestyle 
modification, seven on educational interventions for medication adherence, eight on 
educational interventions for both lifestyle modification and medication adherence, three on 
self-monitoring interventions, four on population-based screening interventions, and two on 
targeted outreach screening interventions. More than half (18 of 34) of the interventions 
studied were provided by non-physicians such as nurses, pharmacists, dietitians, 
psychologists, community health workers, medical students, lay health workers, and peer 
trainers, whereas nine interventions were carried out by physicians and seven were provided 
by a physician and non-physician collaborative team (Table 1).
In terms of the intervention settings, 21 studies were conducted in communities and 13 were 
primarily carried out in community health centers or community hospitals. Around two 
thirds (22 of 34) of the interventions were offered to a large population (>500), whereas the 
rest focused on a small group with <500 hypertensive patients. The study time horizon was 
either short term (≤1 year, n=17) or long term (>1 year, n=17). Twelve studies used an RCT 
design; ten used simulation modeling; and 12 used observational, before-and-after 
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comparison, or other designs to operationalize the analysis. The majority of the studies 
(n=32) used a healthcare system perspective, analyzing only the program cost and the direct 
healthcare cost. The other two studies used a societal perspective and included indirect cost 
such as productivity loss as well. Considerably more studies were published during 2006–
2015 (n=25), and nine studies were published in an earlier period of 1995–2005. Sixteen 
studies were conducted in the U.S. and 18 in other countries including United Kingdom, 
Canada, China, South Africa, Japan, Pakistan, South Korea, Argentina, Israel, and Mexico 
(Table 1).
Among the 34 studies, 13 studies applied a CEA using blood pressure change, changes in 
CHD risk, or life-years gained to measure effectiveness. Eight studies conducted CUA that 
used quality-adjusted life-years (QALYs) gained or disability-adjusted life-years (DALYs) 
averted as effectiveness measures. Thirteen studies used CBA, and the study outcomes were 
monetary values. Three studies applied multiple economic evaluation approaches (Table 2).
Cost-effectiveness Evidence—U.S. Studies
Lifestyle modification—Among the 16 U.S.-based studies, four studies17,19,20,22 
evaluated educational interventions for lifestyle modification, and all the interventions were 
led by non-physician health professionals. In particular, the two RCT studies17,19 concluded 
that the lifestyle education was cost effective, depending on the willingness-to-pay 
threshold. One observational study20 showed that an employer-sponsored and Internet-based 
diet and exercise program was cost saving, and the net savings were $999 per person. 
Finkelstein and colleagues22 assessed the Well-Integrated Screening and Evaluation for 
Women Across the Nation program based on a pre–post study design, and found that it cost 
$714 to reduce CHD risk by 1% or cost $6,683 to gain 1 life-year (Appendix Table 1, 
available online).
Medication adherence—Five studies13,15,16,18,21,23 evaluated educational programs to 
support anti-hypertensive medication adherence, and all five studies (three pharmacist-led 
programs, one team-based program provided by physicians and pharmacists, and one 
physician-led program) concluded that the interventions were cost effective or cost saving. 
Kulchaitanaroaj et al.15 conducted a 6-month RCT study for a collaborative care program to 
provide direct patient education, assessment, and recommendations via phone calls. They 
reported that this educational intervention cost $40 for a 1-mmHg reduction in systolic blood 
pressure (SBP) per hypertensive patient, and $103 for a 1-mmHg reduction in diastolic 
blood pressure. Nuckols and colleagues16 constructed a probability tree model to assess a 
physician-led medication management intervention, and reported that it cost $937 for one 
patient with moderate hypertension to control his or her blood pressure level, and cost $994 
for one severe hypertensive patient to reach the goal. The other three studies18,21,23 on 
pharmacist-led interventions for medication adherence reported that the net savings of the 
programs ranged from $109 to $7,299 per patient, depending on the duration and specific 
elements of the interventions.
Lifestyle modification and medication adherence—Two studies13,14 assessed 
educational interventions that combined lifestyle modification and medication adherence, 
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provided by nurses, community health workers, or peer coaches. The two studies found that 
the combined educational interventions cost from $62 to $114 per patient to reduce 1 mmHg 
in SBP, and the projected cost would be $13,986 to save 1 life-year in a year.
In general, educational interventions in the U.S. in particular included services to support 
medication adherence, and were assessed to be either cost saving or cost effective.
Self-monitoring interventions—Three studies24–26 evaluated self-monitoring 
interventions in the U.S., using automated blood pressure monitors and followed patients 
with interactive voice response technologies or with phone calls. All three interventions 
were provided by non-physician health professionals. Two24,25 of them showed that the self-
monitoring interventions were cost effective. Ritzwoller et al.24 conducted a 2-year RCT 
study and intervened high-risk, low-income hypertensive and obese patients with self-
monitoring devices, and showed that it cost $727 to reduce 1 mmHg in SBP. The modeling 
study of Trogdon et al.25 estimated in a 10-year period that it cost $965 to bring one 
person’s blood pressure under control with self-monitoring of blood pressure. The annual 
cost for saving 1 life-year was predicted to be $2,337 within the 10 years. Wang and 
colleagues26 conducted an RCT and used home blood pressure telemonitoring and 
telephone-based follow-ups. They found that the difference in costs and effectiveness were 
not statistically significant between the treatment group and the control group after 18 
months. But in subgroup analysis, patients with poor blood pressure control at baseline who 
received the intervention significantly improved their blood pressure at 18 months.
Screening and treatment—Two studies27,28 evaluated screening interventions provided 
by physicians. Eddy et al.27 examined hypertension case identification and management 
strategy using an individualized guideline versus the current guideline and found that the net 
saving of the intervention was $1.84 million based on a modeling approach. Wang and 
colleagues28 analyzed screening interventions for high-risk adolescents in the U.S. and 
found that screening plus high blood pressure treatment was cost effective especially among 
boys aged ≥15 years (lifetime ICER = $21,734 per QALY among boys and $56,750 per 
QALY among girls).
Cost-effectiveness Evidence—Studies Outside the U.S
Lifestyle modification—Among the 18 non-U.S.-based studies, six31,32,35,37,40,41 
conducted economic evaluation on educational interventions for lifestyle modification, three 
of which were provided by physicians and three by non-physician health professionals. All 
six studies found the interventions were cost saving or cost effective. The interventions cost 
from $2 (Mexico) to $29 (Pakistan) for a 1-mmHg reduction in SBP. In the United 
Kingdom, the ICER of the educational intervention for behavior change was $17,215 per 
QALY.32 Wang et al.31 conducted a 1-year RCT study and found that the net savings of a 
customized, guideline-oriented lifestyle modification intervention was $32 per person in 
urban areas and $11 in rural areas in China.
Medication adherence—Two studies39,42 examined the educational interventions to 
support medication adherence. A United Kingdom–based RCT study39 found that the 
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intervention, provided by nurse practitioners, was not cost effective. The other study,42 
conducted in South Africa, found the intervention that was led by a physician–pharmacist 
team was cost saving using a non-experimental design.
Lifestyle modification and medication adherence—Another six 
studies29,30,33,34,36,38 evaluated the cost effectiveness of educational interventions for both 
lifestyle change and medication adherence. All except one found the interventions were cost 
saving or cost effective. Among the two studies showing the interventions were cost saving, 
the net savings were estimated at $291 per person in Canada for 1 year and $34,915 per 
person in Japan for 24 years. Lim and colleagues,36 however, found that the combined 
educational intervention was not cost effective when using a more accurate model to 
estimate the benefit–cost ratio in South Korea.
Screening and treatment—Two studies43,45 evaluated population-based screening 
interventions. Gu et al.43 showed that if physicians would screen all adults aged 35–84 years 
and treat all identified stage II hypertensive patients in China, it would cost $9,000 per 
QALY, and was cost effective based on a willingness-to-pay benchmark used in China 
($11,900 per QALY). The study of Howard and colleagues,45 based on those aged 50–69 
years in Australia, showed that the hypertension screening and intensive management 
intervention provided by a physician and non-physician team was projected to cost $613 to 
save 1 QALY using a lifetime Markov model.
Another two studies44,46 examined targeted outreach screening interventions carried out by a 
physician and non-physician team. The study of Yosefy et al.,46 conducted in Israel, showed 
that the outreach intervention was cost saving (ICER= −$3,257 per LYS). The study of Zhao 
and colleagues,44 based in Australia, showed the outreach intervention in remote 
communities among indigenous residents aged ≥15 years was cost effective in a 10-year 
time period (ICER=$1,131–$1,974 per year of life lost if followed up with medium level of 
primary care and $3,422–$5,637 per year of life lost if followed up with high level of 
primary care).
Assessing the Quality of the Literature—Based on the 19 criteria items from the 
Consensus on Health Economic Criteria,10 the quality of the economic evaluations varied 
substantially. All 34 studies clearly described the study population, posed a research 
question in answerable form, appropriately stated the actual study perspective, and 
appropriately measured the costs and outcomes (Appendix Table 2, available online). Four 
weaknesses were identified in this literature. First, nearly a third (32%) of the articles did not 
use an experimental or quasi-experimental design to identify a causal relationship. They 
either used a pre–post comparison with no control group, or used observational data without 
appropriate statistical adjustment (e.g., pseudo-randomization with propensity score 
matching). Second, more than half (53%) of the articles did not appropriately value the 
costs. Those studies did not conduct discounting or inflation adjustment when their 
interventions lasted >1 year. Third, in about 44% of the articles, the researchers did not 
perform sensitivity analyses when there were uncertainties in the study parameters; thus, the 
robustness of the results was questionable. Finally, only 47% of the studies declared any 
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potential conflict of interest, and only 76% appropriately discussed ethical and distributional 
issues.
DISCUSSION
In general, the reviewed literature suggests cost-effectiveness research on community-based 
hypertension interventions has mainly focused on health education interventions, such as 
promotion of lifestyle change and support for medication adherence. Although the details of 
the interventions varied significantly, the majority of studies (23 of 25) concluded that 
educational interventions were cost effective or cost saving. The median ICER of 
educational interventions in the U.S. was $62 (ranged from $40 to $114) for a 1-mmHg 
reduction in SBP per hypertensive patient and was $13,986 (ranged from $6,683 to $58,610) 
for 1 life-year gained. Outside the U.S., educational intervention cost from $0.62 (China) to 
$29 (Pakistan) for a 1-mmHg reduction in SBP. One in three studies on self-monitoring 
interventions found the intervention was not cost effective, and all studies on population 
screening interventions found these interventions were cost effective or cost saving. Also, 
study findings were not summarized separately for developed and developing countries. 
Intervention costs to reduce 1 mmHg blood pressure, 1 life-year gained, or QALY were 
substantially higher in the U.S. than in other high-income countries. Some researchers have 
suggested that the cost per QALY threshold in the U.S should be $100,000 or $150,000, 
given that the per capita income in the U.S. is roughly $54,000 and WHO has suggested that 
a cost-effectiveness threshold be set at three times per capita gross domestic product.47
A recent systematic review7 found that team-based care that consists of patients, primary 
care providers, and other health professionals to improve blood pressure control was cost 
effective based on economic results from ten studies. Except for this study, economic 
evidence for other community-based interventions is largely uncertain in the literature. Other 
review studies examined only the effectiveness rather than cost effectiveness of community-
based hypertension interventions. For instance, a systematic review5 found that community 
programs for hypertension prevention could reduce 10-year CVD risk by 0.65% on average, 
a modest but significantly favorable outcome in CVD risk score. A Cochrane review6 found 
that self-monitoring interventions resulted in a moderate reduction in SBP and diastolic 
blood pressure, and educational interventions did not lead to a large net reduction in SBP. 
This review study contributed to the literature by reviewing the most up-to-date economic 
evidence of the common community-based interventions for hypertension control.
More than half of the studies (18 of 34) evaluated the interventions provided by non-
physician healthcare practitioners, such as nurse practitioners, pharmacists, dietitians, 
psychologists, community health workers, peer trainers, and others, whereas the other 16 
studies were undertaken by either physicians or physician and non-physician healthcare 
teams. In general, the findings of cost effectiveness were not greatly influenced by the types 
of providers. However, because of a limited number of studies, the magnitudes of ICERs 
cannot be directly compared.
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Limitations
Caution should be taken when interpreting these findings given the limitations of the 
literature. First, half of the studies (17 of 34) evaluated interventions that were less than 1 
year in duration. This could be problematic regarding understanding the sustainability and 
longer-term cost effectiveness of those programs. As the time horizon is usually an 
important determinant of the ICER of an intervention, results could differ substantially 
between short-term and long-term study periods of comparison when analyzing the 
economic implication of interventions on a yearly basis. For instance, Hollenbeak et al.14 
showed that in 6 months, the ICER of the educational intervention was $47 per mmHg 
reduction in SBP and $453,419 per CHD event avoided. However, in a 10-year time horizon, 
the ICER was predicted to be only $3,998 per incremental QALY. Second, studies were 
conducted in various settings and countries that have very different healthcare systems. 
Specific context would affect the implementation process and health providers’ compliance 
with the intervention protocols. Thus, their findings cannot be generalized to other settings. 
Finally, many studies did not use an RCT design, nor did they have a control group to do a 
quasi-experimental analysis. In addition, about 44% of the studies did not take uncertainty 
into consideration, and sensitivity analyses were not performed. These issues might affect 
the quality of the literature.
To improve the research quality, a randomized controlled design or a quasi-experimental 
design with comparable comparison groups should be considered for future studies. 
Economic modeling and subgroup analysis are better approaches for a comprehensive 
economic evaluation when person-level information is available. With regard to study 
perspectives, although the healthcare system perspective is most widely used, a societal 
perspective can sometimes provide more information about the effects of hypertension 
control on the society. For example, costs of transportation and informal caregiving are often 
neglected in the economic studies. Moreover, when cost information includes several years 
of cost, it is necessary to appropriately inflate or deflate the cost to a chosen year. The same 
is true of health outcomes. For example, discounting QALYs are often used when the study 
time horizon is more than 1 year. To confirm the robustness of results, conducting sensitivity 
analyses is strongly recommended.
Furthermore, a cost-effectiveness benchmark was presented only in nine studies, and 11 
others suggested their results were cost effective but did not provide a benchmark. If a 
prevention strategy is not cost saving, it may be plausible to incorporate a benchmark to 
inform decision making. For example, the $50,000 cost per QALY is a widely used 
benchmark value, but it is arbitrary and does not take into account changes over time in 
purchasing power.47 Also, researchers examined the cost effectiveness of hypertension 
control interventions using various health outcomes to measure effectiveness, and this makes 
it difficult to compare interventions. Future studies can be based on the current evidence and 
carefully select effectiveness measures. Finally, not all studies specified whether conflicts of 
interest were present. For example, studies may be funded by the government, research 
foundations, industries, or other agencies, which potentially convey a conflict of interest. It 
may be important for researchers to be transparent if there is a conflict.
Zhang et al. Page 9
Am J Prev Med. Author manuscript; available in PMC 2018 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CONCLUSIONS
This review found that community-based interventions targeting health behavior change and 
medication adherence were considered cost effective and may even reduce long-term 
healthcare costs. Community interventions that incorporate non-physician providers, such as 
community health workers, into the U.S. healthcare system may be favorable from a cost-
effectiveness perspective. For example, some states have expanded preventive services 
provided by community health workers or other non-physician health professionals under 
Medicaid.48 Further research may focus on economic evaluations of those innovative service 
models in a real-world setting to assess their long-term effectiveness and economic 
implications.
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Figure 1. 
Selection of cost-effectiveness literature on community-based interventions for hypertension 
control based on PRISMA flow diagram, 1995–2015.
Note: Searched key words: (1) Interventions: “community health worker” or “community-
based” or “community-based interventions” “community-clinical coordination” or “outreach 
services” or “culturally competent services” or “promoters” or “community health 
education.” (2) Outcomes: “hypertension” or “high blood pressure” or “diastolic” “systolic” 
or “Quality adjusted life years” or “QALYs” or “life years gained” or “disability-adjusted 
life years” or “DALYs” or “adherence to anti-hypertensive medication.” (3) Study type: 
“Cost-benefit” or “cost-effectiveness” or “cost-utility” or “economic evaluation” or “budget 
impact analysis.”
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Table 1
Main Characteristics of Cost-Effectiveness Studies on Community-Based Interventions for Hypertension 
Control, 1995–2015 (N=34)
Characteristics Studies, n
Intervention
 Educational interventions
  Lifestyle modification 10
  Medication adherence 7
  Lifestyle modification and medication adherence 8
  Self-monitoring of blood pressure interventions 3
 Screening interventions
  Population-based screening 4
  Outreach screening 2
Provider
 Physicians 9
 Non-physician providers 18
 Both physician and non-physician providersa 7
Intervention setting
 Communities 21
 Community health centers/hospitals/general practitioners 13
Population size
 Small (≤500) 12
 Large (>500) 22
Time horizon
 Short-term (≤ 1 year) 17
 Long-term (> 1 year) 17
Study design
 Randomized trial 12
 Modeling 10
 Others 12
Perspective
 Healthcare system 32
 Societal 2
Published period
 1995–2005 9
 2006–2015 25
Country
 U.S. 16
 Other countries 18
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aNon-physician providers include nurses, pharmacists, dietitians, psychologists, community health workers, medical students, lay health workers, 
and peer trainers.
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